neutralizing antibody for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. anti-inflammatoty and immuno-therapy
vs. Immunostimulants drugs
vs. neutralizing antibody
vs. casirivimab/imdevimab (Ronapreve)
vs. control
vs. placebo
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 2

table network network 2

display ongoing demontrated benefit only

popup

BLAZE-2 US (Cohen), 2021 NCT04497987

bamlanivimab monotherapy vs. placebo

COVID-19 prophylaxis (excluding children)

O'Brien (Part A: uninfected household contacts), 2021 NCT04452318

casirivimab/imdevimab (Ronapreve) vs. placebo

COVID-19 prophylaxis (excluding children)

Isa, 2021 NCT04519437

casirivimab/imdevimab (Ronapreve) vs. placebo

COVID-19 prophylaxis (excluding children)

Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 NCT04452318

casirivimab/imdevimab (Ronapreve) vs. placebo

COVID-19 prophylaxis (excluding children)

Jurdi, 2022

cilgavimab and tixagevimab (Evusheld) vs. control

COVID-19 prophylaxis (excluding children)

PROVENT, 2022 NCT04625725

cilgavimab and tixagevimab (Evusheld) vs. placebo

COVID-19 prophylaxis (excluding children)

STORM CHASER, 2021 NCT04625972

cilgavimab and tixagevimab (Evusheld) vs. placebo

COVID-19 prophylaxis (excluding children)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open